Abstract: The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins.

Abstract: A display device is provided. The display device includes a first substrate, a first charge trap layer disposed on the first substrate and including silicon nitride, a semiconductor layer disposed on the first charge trap layer and including a first active layer of a first transistor and a second active layer of a second transistor, and an organic light emitting element electrically connected to the first transistor, wherein a ratio of a content of a Si element to a content of an N element in the first charge trap layer is in a range of 1.6 to 2.5.

Abstract: Provided is a method for preparing single-walled carbon nanotubes (SWCNTs), including the steps of: (a) depositing a metal catalyst in the form of single atom or atomic cluster on a catalyst support to prepare a single-atom catalyst or an atomic cluster catalyst; and (b) growing carbon nanotubes on the single-atom catalyst or the atomic cluster catalyst to prepare single-walled carbon nanotubes (SWCNTs). According to the method, it is possible to uniformly mass-produce single-walled carbon nanotubes (SWCNTs) having excellent heat conductivity, electroconductivity, mechanical strength, dispersibility, or the like.

Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Abstract: An embodiment of the invention provides a display device including: a substrate; a first transistor comprising a first semiconductor layer and a second transistor comprising a second semiconductor layer, the first and second semiconductor layers positioned on the substrate; a light emitting diode connected to the first transistor, wherein: the first transistor is a driving transistor; the second transistor is a switching transistor; a first concentration of fluorine included in the first semiconductor layer is higher than a second concentration of fluorine in the second semiconductor layer; and a first difference between the first and second concentrations substantially at or near a first interface of the first and second semiconductor layers is larger than a second difference between the first and second concentrations at a second interface of the first and second semiconductor layers, the second interface further from the substrate than the first interface.

Abstract: The present invention relates to coronavirus infectious disease COVID-19 therapeutic proteins CTP alpha, CTP beta, CTP gamma, CTP delta, and uses thereof. Compared to a known peptide (P6) which mimics the binding site of a receptor binding domain (RBD) of SARS-CoV and angiotensin-converting enzyme 2 (ACE2), the therapeutic proteins CTP alpha, CTP beta, CTP gamma, and CTP delta according to the present invention comprise a novel part obtained by adding a novel sequence of amino acids, wherein the interaction of atoms constituting the amino acids has been fundamentally designed in order to strengthen the binding of SARS-CoV2 to a novel epitope of RBD.

Abstract: A display device includes: a substrate; a transistor positioned on the substrate; and a light-emitting device electrically connected to the transistor, wherein the substrate includes a first layer, a second layer positioned between the first layer and the transistor, and a third layer positioned between the second layer and the transistor, the first layer and the third layer include organic materials, and the organic material included by the first layer and the organic material included by the third layer have different half-lives for a corona discharge.

Abstract: The present invention relates to a peptide for treatment of the corona virus infection COVID-19 and a use thereof. In order to make the binding to the new epitope of SARS-CoV2 RBD stronger compared to the peptide (P6) simulating the conventionally known binding site between SARS-CoV RBD and ACE2, the peptide of the present invention includes a new portion added with a novel amino acid sequence fundamentally designed for interaction in the dimension of atoms consisting of the amino acids. Suggested in the present invention is a novel design of a peptide having higher binding affinity than conventionally known peptides, wherein an expanded peptide is creatively designed to additionally interact with charged amino acids of D420 and K458, located at the rear side of the known binding boundary between RBD and hACE2. The peptide of the present invention exhibits high possibility as a therapeutic agent for COVID-19.

Abstract: One aspect of the disclosure relates to a cargo delivery system comprising an autophagy targeting ligand and a target-binding ligand. In one aspect of the disclosure, by comprising an autophagy targeting ligand, cargo, which is a target-binding ligand that specifically binds to a target, is delivered to the p62 protein and autophagy is activated, so that depending on the type of target-binding ligand used, a target to be degraded can be selectively and directly removed. Accordingly, the cargo delivery system according to an aspect of the disclosure may be used in pharmaceutical compositions or food compositions for preventing, alimerating, and treating various diseases.

Abstract: According to various aspects and exemplary embodiments of the present disclosure, ultra-small catalyst particles having extremely high reactivity may be synthesized in single-atom or single-molecule state. When the ultra-small-sized single-atom or single-molecule catalyst is used, the use of metal raw materials can be minimized and, at the same time, catalytic activity may be maximized through maximized reactivity of the single-atom or single-molecule catalyst.

Abstract: An organic light-emitting device including a first compound represented by Formula 1 and a second compound represented by one of Formulae 2A and 2B.

Abstract: A display device includes a first thin film transistor disposed on a substrate. A first insulating interlayer covers the first thin film transistor. An active pattern is disposed on the first insulating interlayer. The active pattern includes indium-gallium-zinc oxide (IGZO) having a thickness in a range of about 150 ? to about 400 ?. A gate insulation layer covers the active pattern. A gate pattern is disposed on the gate insulation layer. A second insulating interlayer covers the gate pattern.

Abstract: An organic light-emitting device including a first compound represented by Formula 1 and a second compound represented by one of Formulae 2A and 2B.

Abstract: A display device includes a base substrate including a first substrate and a second substrate sequentially laminated, a lower semiconductor layer disposed on at least one of the first substrate and the second substrate, a buffer layer disposed on the base substrate, an active semiconductor layer disposed on the buffer layer and including a first active layer of a first transistor and a second active layer of a second transistor, a first insulating layer disposed on the active semiconductor layer, and a first conductive layer disposed on the first insulating layer and including a first gate electrode of the first transistor and a second gate electrode of the second transistor, wherein the lower semiconductor layer overlaps the first active layer, and does not overlap the second active layer.

Abstract: Novel p62 ligand compounds, or a stereoisomer, a solvate, a hydrate, or a prodrug thereof are disclosed. The novel compounds, stereoisomer, solvate, hydrate, or prodrug activates selective autophagy in cells to selectively remove proteins, organelles, and coagulations in the body, and thus can be advantageously used as a pharmaceutical composition for preventing, ameliorating, or treating various proteinopathies. Compositions such as pharmaceutical composition or food compositions containing the novel p62 ligand compounds, stereoisomer, solvate, hydrate, or prodrug thereof as well as uses thereof are disclosed.

Abstract: The present disclosure relates to a composition comprising a Lactobacillus plantarum CJLP475 strain deposited under Accession No. KCCM12287P; and a Lactobacillus plantarum CJLPl7 strain deposited under Accession No. KCCM12249P, and use thereof.

Abstract: The present disclosure relates to a novel Lactobacillus plantarum CJLP475 strain having acid-resistance, bile-resistance and an immune-enhancing activity, and a composition including the same.

Abstract: A composition has effects for promoting endoplasmic reticulum (ER)-phagy, a composition for maintaining ER homeostasis or reducing ER stress, and a pharmaceutical composition for preventing and/or treating ER-stress-related diseases. The composition contains a p62 ligand compound as an active ingredient. The p62 ligand compound can modulate p62 to interact with a receptor associated with autophagic degradation of ER component, modulate oligomerization and/or aggregation of the receptor, modulate formation of autophagosomes, and the like. Thus, uses of p62 ligand compound in inducing ER-autophagy are provided.

Abstract: The present disclosure relates to a composition comprising a Lactobacillus plantarum CJLP475 strain deposited under Accession No. KCCM12287P; and a Lactobacillus plantarum CJLP243 strain deposited under Accession No. KCCM11045P, and use thereof.

Abstract: A nitrogen-doped catalyst for oxidative coupling of methane, which is a catalyst for obtaining a C2 hydrocarbon product with high yield, and a method for manufacturing the catalyst are provided. An embodiment of the present inventive concept relates to a nitrogen-doped catalyst for oxidative coupling of methane having a silica support; and sodium tungstate and manganese supported on the support.